Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer.
Min HuangM Catherine PietanzaAyman SamkariJames PellissierThomas BurkeSheenu ChandwaniFansen KongA Simon PickardPublished in: PharmacoEconomics (2020)
Pembrolizumab showed significant improvement in Q-TWiST compared to chemotherapy in advanced or metastatic NSCLC in both previously untreated and treated patients. The benefits of pembrolizumab continued to accrue with longer follow-ups.
Keyphrases
- advanced non small cell lung cancer
- small cell lung cancer
- newly diagnosed
- squamous cell carcinoma
- end stage renal disease
- epithelial mesenchymal transition
- ejection fraction
- chronic kidney disease
- prognostic factors
- epidermal growth factor receptor
- patient reported
- signaling pathway
- tyrosine kinase
- brain metastases
- data analysis